Keyword search (4,163 papers available)

"lung" Keyword-tagged Publications:

Title Authors PubMed ID
1 Lung Nodule Malignancy Classification Integrating Deep and Radiomic Features in a Three-Way Attention-Based Fusion Module Khademi S; Heidarian S; Afshar P; Mohammadi A; Sidiqi A; Nguyen ET; Ganeshan B; Oikonomou A; 41150036
ENCS
2 Virtual reality-based preoperative planning for optimized trocar placement in thoracic surgery: A preliminary study Harirpoush A; Rakovich G; Kersten-Oertel M; Xiao Y; 39720764
ENCS
3 Translating the Interplay of Cognition and Physical Performance in COPD and Interstitial Lung Disease: Meeting Report and Literature Review Rozenberg D; Reid WD; Camp P; Campos JL; Dechman G; Davenport PW; Egan H; Fisher JH; Guenette JA; Gold D; Goldstein RS; Goodridge D; Janaudis-Ferreira T; Kaplan AG; Langer D; Marciniuk DD; Moore B; Orchanian-Cheff A; Otoo-Appiah J; Pepin V; Rassam P; Rotenberg S; Ryerson C; Spruit MA; Stanbrook MB; Stickland MK; Tom J; Wentlandt K; 38901488
HKAP
4 Curcumin inhibition of bleomycin-induced changes in lung collagen synthesis, deposition and assembly Durairaj P; Venkatesan S; Narayanan V; Babu M; 34643929
BIOLOGY
5 Defective GaAs nanoribbon-based biosensor for lung cancer biomarkers: a DFT study Tarun T; Singh P; Kaur H; Walia GK; Randhawa DKK; Choudhary BC; 34459994
ENCS
6 Circulating miR-1246 Targeting UBE2C, TNNI3, TRAIP, UCHL1 Genes and Key Pathways as a Potential Biomarker for Lung Adenocarcinoma: Integrated Biological Network Analysis Huang S; Wei YK; Kaliamurthi S; Cao Y; Nangraj AS; Sui X; Chu D; Wang H; Wei DQ; Peslherbe GH; Selvaraj G; Shi J; 33050659
CHEMBIOCHEM
7 Protective effects of curcumin on bleomycin-induced changes in lung glycoproteins. Durairaj P, Venkatesan S, Narayanan V, Babu M 32350681
BIOLOGY
8 Performance monitoring in lung cancer patients pre- and post-chemotherapy using fine-grained electrophysiological measures Simó M; Gurtubay-Antolin A; Vaquero L; Bruna J; Rodríguez-Fornells A; 29387526
MLNP

 

Title:Performance monitoring in lung cancer patients pre- and post-chemotherapy using fine-grained electrophysiological measures
Authors:Simó MGurtubay-Antolin AVaquero LBruna JRodríguez-Fornells A
Link:https://pubmed.ncbi.nlm.nih.gov/29387526/
DOI:10.1016/j.nicl.2017.12.032
Publication:NeuroImage. Clinical
Keywords:ChemobrainCognitive impairmentError-related negativity (ERN)Event-related potentials-ERPLung cancerPerformance monitoring
PMID:29387526 Category:Neuroimage Clin Date Added:2019-06-07
Dept Affiliation: MLNP
1 Cognition and Brain Plasticity Group, Bellvitge Biomedical Research Institute-IDIBELL, L'Hospitalet de Llobregat, 08907 Barcelona, Spain; Neuro-Oncology Unit, Hospital Universitari de Bellvitge-ICO L'Hospitalet-IDIBELL, 08907 Barcelona, Spain. Electronic address: msimo@iconcologia.net.
2 Cognition and Brain Plasticity Group, Bellvitge Biomedical Research Institute-IDIBELL, L'Hospitalet de Llobregat, 08907 Barcelona, Spain.
3 Cognition and Brain Plasticity Group, Bellvitge Biomedical Research Institute-IDIBELL, L'Hospitalet de Llobregat, 08907 Barcelona, Spain; Laboratory for Motor Learning and Neural Plasticity, Concordia University, HUB 1R6 Montreal, QC, Canada.
4 Neuro-Oncology Unit, Hospital Universitari de Bellvitge-ICO L'Hospitalet-IDIBELL, 08907 Barcelona, Spain.
5 Cognition and Brain Plasticity Group, Bellvitge Biomedical Research Institute-IDIBELL, L'Hospitalet de Llobregat, 08907 Barcelona, Spain; Dept. of Cognition, Development and Education Psychology, University of Barcelona, Campus Bellvitge, L'Hospitalet de Llobregat, 08907 Barcelona, Spain; Catalan Institution for Research and Advanced Studies, ICREA, 08010 Barcelona, Spain.

Description:

No previous event-related potentials (ERPs) study has explored the error-related negativity (ERN) - an ERP component indexing performance monitoring - associated to cancer and chemotherapy-induced cognitive impairment in a lung cancer population. The aim of this study was to examine differences in performance monitoring in a small-cell lung cancer group (SCLC, C +) 1-month following chemotherapy and two control groups: a non-small cell lung cancer patient group (NSCLC, C -) prior to chemotherapy and a healthy control group (HC). Seventeen SCLC (C +) underwent a neuropsychological assessment and an ERP study using a flanker and a stop-signal paradigm. This group was compared to fifteen age-, gender- and education-matched NSCLC (C -) and eighteen HC. Between 20 and 30% of patients in both lung cancer groups (C + and C -) met criteria for cognitive impairment. Concerning ERPs, lung cancer patients showed lower overall hit rate and a severe ERN amplitude reduction compared to HC. Lung cancer patients exhibited an abnormal pattern of performance monitoring thus suggesting that chemotherapy and especially cancer itself, may contribute to cognitive deterioration. ERN appeared as an objective laboratory tool sensitive to cognitive dysfunction in cancer population.





BookR developed by Sriram Narayanan
for the Concordia University School of Health
Copyright © 2011-2026
Cookie settings
Concordia University